of Participants (Studies) Follow-up Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with Control Risk Difference with Aspirin (95% CI) All-cause mortality Up to 4 y Lowa,b because of imprecision Moderate-Risk Populationd (from 3 fewer to 3 more) Recurrent VTE 1,224 Up to 4 y Moderatea because of imprecision (from 24 fewer to 89 fewer) Major bleeding 1,224 Up to 4 y Moderatea,b because of imprecision (from 6 fewer to 29 more) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ASPIRE Aspirin to Prevent Recurrent Venous Thromboembolism; HR hazard ratio; INSPIRE International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism; WARFASA Aspirin for the Prevention of Recurrent Venous Thromboembolism (the Warfarin and Aspirin) study. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence. a The Brighton et al70 study was stopped early and included only one-third of the intended patients. b CI includes values suggesting no effect and values suggesting either bene t or harm. c Estimate based on Simes et al72 (INSPIRE) of synthesis of Brighton et al70 (ASPIRE) and Becattini et al71 (WARFASA). 